Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
14
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Cervical Cancer Screening to provide further recommendations for a subset of women with conflicting results on cervical cytology/Pap tests and Human papillomavirus (HPV) High Risk DNA tests.
08
In this recent study, researchers in the United States conducted a study To compare the dose distribution between customized planning (CP) and adopting a single plan (SP) in multifractionated high-dose-rate brachytherapy and to establish predictors for the necessity of CP in a given patient. A total of 50 computed tomography-based plans for 10 patients were evaluated.
According to recent research from the United States, The absence of highly sensitive and specific serum biomarkers makes mass screening for ovarian cancer impossible. The claudin proteins are frequently overexpressed in ovarian cancers, but their potential as prognostic, diagnostic, or detection markers remains unclear.
07
A U.S. Phase 1 clinical trial is under way to determine if a new anti-cancer drug is safe and effective for use in patients with solid cancer tumors. The drug, currently called EP-100, is designed to treat common breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers. It is being tested by TGen Clinical Research Services at Scottsdale (Ariz.) Healthcare's Piper Cancer Center.
01
Cervical cancer could be eradicated within the next 50 years if countries implement national screening programmes based on detection of the human papilloma virus (HPV), which causes the disease, together with vaccination programmes against the virus, according to a cervical cancer screening expert.
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
Cell Therapeutics, Inc. announced that it will re-focus its resources on the approval of OPAXIO for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm.
29
Whispering Oaks International, Inc., d/b/a Biocurex, announced today that it is making two presentations at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) being held this week in Amsterdam, The Netherlands. BioCurex's presentations address its RECAF cancer market test in combination with other currently used cancer markers: CA-125 for ovarian cancer and CEA for colorectal cancer.
26
Presymptomatic gene mutation testing has been available for individuals at risk for hereditary breast and ovarian cancer (HBOC) for 15 years (Miki et al., 1994). This has created a category of individuals with specific genetic mutations who are well but living with knowledge that it is highly probable they will become ill in the future. Little is known about how individuals live with such knowledge beyond the months immediately following testing.
25
Newer, more accurate, screening combined with a program of human papilloma vaccination could eradicate cervical cancer, a British researcher said.
We care about your feedback. Let us know how we can improve your CancerCompass experience.